IMMUNE-RESPONSE TO A RECOMBINANT HEPATITIS-B VACCINE IN HEMODIALYSIS-PATIENTS

被引：10

作者：

DOCCI, D ^{[1
]}

CIPOLLONI, PA ^{[1
]}

BALDRATI, L ^{[1
]}

CAPPONCINI, C ^{[1
]}

TURCI, F ^{[1
]}

FELETTI, C ^{[1
]}

机构：

[1] OSPED GEN PROVINCIALE M BUFALINI,ANAL LAB,CESENA,ITALY

来源：

INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS | 1990年 / 13卷 / 07期

关键词：

D O I：

10.1177/039139889001300712

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

A 20-μg dose of a recombinant hepatitis B vaccine was given at 0, 1, 2 and 6 months to 24 hemodialysis patients. From month 7 (i.e., 1 month after the fourth injection), 58.3% (14/24) of the patients had developed protective levels of antibodies against hepatitis B surface antigen (anti-HBs). In patients responding to vaccination, the fourth injection led to an abrupt rise of the anti-HBs titres which reached their maximum 2 months later, that is, in month 8. At that time, the geometric mean titre of anti-HBs was 145.79 mlU/ml. Eighteen months after the start of vaccination, 50% (12/24) of the patients were maintaining protective levels of anti-HBs antibodies. It is noteworthy that these results could be obtained with a considerably lower dosage than previously recommended.

引用

页码：451 / 453

页数：3

共 7 条

[1]

BRAMWELL SP, 1985, LANCET, V1, P1412

[2]

BRUGUERA M, 1987, POSTGRAD MED J, V63, P155

[3]

CROSNIER J, 1989, REPLACEMENT RENAL FU, P881

[4] IMMUNOGENICITY OF RECOMBINANT HEPATITIS-B VACCINE IN DIALYSIS PATIENTS [J].